DK3697784T5 - Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser - Google Patents

Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser Download PDF

Info

Publication number
DK3697784T5
DK3697784T5 DK18788711.2T DK18788711T DK3697784T5 DK 3697784 T5 DK3697784 T5 DK 3697784T5 DK 18788711 T DK18788711 T DK 18788711T DK 3697784 T5 DK3697784 T5 DK 3697784T5
Authority
DK
Denmark
Prior art keywords
imidazo
treatment
pharmaceutical compositions
inflammatory disorders
pyridine compounds
Prior art date
Application number
DK18788711.2T
Other languages
Danish (da)
English (en)
Other versions
DK3697784T3 (da
Inventor
Der Plas Steven Emiel Van
Oscar Mammoliti
Sébastien Laurent Xavier Martina
Pieter Isabelle Roger Claes
Ghjuvanni Petru Diunisu Coti
Denis Maurice Annoot
Ramos Miriam López
René Alexandre Galien
David Amantini
Reginald Christophe Xavier Brys
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of DK3697784T3 publication Critical patent/DK3697784T3/da
Publication of DK3697784T5 publication Critical patent/DK3697784T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18788711.2T 2017-10-20 2018-10-11 Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser DK3697784T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
DK3697784T3 DK3697784T3 (da) 2023-10-30
DK3697784T5 true DK3697784T5 (da) 2024-01-15

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18788711.2T DK3697784T5 (da) 2017-10-20 2018-10-11 Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser

Country Status (30)

Country Link
US (3) US11564923B2 (cg-RX-API-DMAC7.html)
EP (2) EP4265254A3 (cg-RX-API-DMAC7.html)
JP (2) JP7292271B2 (cg-RX-API-DMAC7.html)
KR (1) KR102757425B1 (cg-RX-API-DMAC7.html)
CN (2) CN117534670A (cg-RX-API-DMAC7.html)
AR (1) AR113784A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018350592B2 (cg-RX-API-DMAC7.html)
CA (1) CA3079449A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020005200A2 (cg-RX-API-DMAC7.html)
DK (1) DK3697784T5 (cg-RX-API-DMAC7.html)
ES (1) ES2967432T3 (cg-RX-API-DMAC7.html)
FI (1) FI3697784T5 (cg-RX-API-DMAC7.html)
GB (1) GB201717260D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063998T2 (cg-RX-API-DMAC7.html)
IL (2) IL273943B2 (cg-RX-API-DMAC7.html)
LT (1) LT3697784T (cg-RX-API-DMAC7.html)
MA (1) MA50391B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003863A (cg-RX-API-DMAC7.html)
MY (1) MY205443A (cg-RX-API-DMAC7.html)
PH (1) PH12020550230A1 (cg-RX-API-DMAC7.html)
PL (1) PL3697784T3 (cg-RX-API-DMAC7.html)
PT (1) PT3697784T (cg-RX-API-DMAC7.html)
RS (1) RS64800B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003516TA (cg-RX-API-DMAC7.html)
SI (1) SI3697784T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300377T1 (cg-RX-API-DMAC7.html)
TW (2) TWI805629B (cg-RX-API-DMAC7.html)
WO (1) WO2019076716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002166B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ, インコーポレイテッド イオンチャネルモジュレーター
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
MX2024000517A (es) 2021-07-12 2024-01-31 Galapagos Nv Tratamiento de enfermedades inflamatorias.
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP7882100B2 (ja) * 2022-12-07 2026-06-30 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
EP4652166A1 (en) 2023-01-18 2025-11-26 Galapagos N.V. Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders
CN120584114A (zh) 2023-01-19 2025-09-02 加拉帕戈斯股份有限公司 用于治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病和增生性疾病的咪唑并[4,5-b]吡啶衍生物
WO2026098666A1 (zh) * 2024-11-11 2026-05-15 杭州领业医药科技有限公司 一种tyk2抑制剂的共晶及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) * 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
US12472181B2 (en) 2025-11-18
SG11202003516TA (en) 2020-05-28
GB201717260D0 (en) 2017-12-06
KR102757425B1 (ko) 2025-01-20
PT3697784T (pt) 2024-01-09
RS64800B1 (sr) 2023-11-30
IL302615B1 (en) 2024-06-01
EP4265254A3 (en) 2024-03-13
AU2023201522A1 (en) 2023-04-13
LT3697784T (lt) 2023-10-25
CN117534670A (zh) 2024-02-09
RU2020116376A (ru) 2021-11-22
IL302615A (en) 2023-07-01
FI3697784T5 (fi) 2024-01-12
IL273943A (en) 2020-05-31
AR113784A1 (es) 2020-06-10
JP7292271B2 (ja) 2023-06-16
SMT202300377T1 (it) 2024-01-10
MY205443A (en) 2024-10-22
EP3697784B1 (en) 2023-10-04
SI3697784T1 (sl) 2023-11-30
CN111225916B (zh) 2023-11-03
IL302615B2 (en) 2024-10-01
CN111225916A (zh) 2020-06-02
MA50391B1 (fr) 2023-11-30
KR20200074178A (ko) 2020-06-24
JP2020537672A (ja) 2020-12-24
WO2019076716A1 (en) 2019-04-25
CA3079449A1 (en) 2019-04-25
PL3697784T3 (pl) 2024-03-11
CO2020005200A2 (es) 2020-05-29
IL273943B2 (en) 2023-10-01
US20210169879A1 (en) 2021-06-10
US11564923B2 (en) 2023-01-31
ZA202002166B (en) 2021-05-26
EP4265254A2 (en) 2023-10-25
TWI805629B (zh) 2023-06-21
TWI866258B (zh) 2024-12-11
AU2018350592B2 (en) 2022-12-22
TW201918483A (zh) 2019-05-16
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
HRP20231315T1 (hr) 2024-02-16
US20230310433A1 (en) 2023-10-05
MA50391A (fr) 2021-04-21
FI3697784T3 (fi) 2023-10-31
HUE063998T2 (hu) 2024-02-28
AU2023201522B2 (en) 2024-11-28
MX2020003863A (es) 2020-08-13
EP3697784A1 (en) 2020-08-26
RU2020116376A3 (cg-RX-API-DMAC7.html) 2021-11-22
TW202411229A (zh) 2024-03-16
PH12020550230A1 (en) 2021-02-08
BR112020007541A2 (pt) 2020-09-24
JP7654031B2 (ja) 2025-03-31
JP2023113834A (ja) 2023-08-16
DK3697784T3 (da) 2023-10-30
US20260183288A1 (en) 2026-07-02
AU2018350592A1 (en) 2020-06-04
ES2967432T3 (es) 2024-04-30

Similar Documents

Publication Publication Date Title
DK3697784T3 (da) Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3478679T3 (da) 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
EP3873900C0 (en) IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS INTEGRIN ALPHA4BETA7 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
DK3269716T3 (da) Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3348557T3 (da) Imidazo[1,2-a]pyridiner til behandling eller forebyggelse af hyperurekæmi eller gigt
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3380471T3 (da) Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
DK3500571T3 (da) Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL246823A0 (en) History of benzimidazole and their pharmaceutical preparations for the treatment of inflammatory disorders
DK3535263T3 (da) Substituerede pyrido[3,4-b]indoler til behandling af bruskforstyrrelser
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3458440T3 (da) Pyridinethioner, farmaceutiske sammensætninger deraf, og terapeutisk anvendelse til behandling af en proliferativ, inflammatorisk, neurodegenerativ eller immunmedieret sygdom
PL3723807T3 (pl) Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
DK3515409T3 (da) Kompleks og sammensætninger til behandling af oftalmologiske og dermatologiske sygdomme
DK3612174T3 (da) Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion
DK3319586T3 (da) Farmaceutisk formulering til behandling af inflammatoriske forandringer i endetarmen